Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

14.010
-0.110-0.78%
Volume:7.67M
Turnover:107.11M
Market Cap:15.89B
PE:-11.16
High:14.220
Open:14.110
Low:13.790
Close:14.120
52wk High:35.500
52wk Low:12.310
Shares:1.13B
HK Float Shares:1.13B
Volume Ratio:0.94
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.256
ROE:-22.56%
ROA:-12.16%
PB:2.83
PE(LYR):-11.16
PS:4.41

Loading ...

BRIEF-Zai Lab Announces National Medical Products Administration (Nmpa) Approval Of Augtyro™

Reuters
·
Jan 06

China Approves Zai Lab's AUGTYRO for NTRK-Positive Solid Tumors

Reuters
·
Jan 06

Zai Lab Announces National Medical Products Administration (Nmpa) Approval of Augtyro™ (Repotrectinib) for Patients With Ntrk-Positive Solid Tumors

THOMSON REUTERS
·
Jan 06

Zai Lab to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

Zai Lab Officer Rafael Amado Reports Sale of Common Shares

Reuters
·
Jan 03

Asian Equities Traded in the US as American Depositary Receipts Climb in Friday Trading

MT Newswires Live
·
Jan 02

Stock Track | Zai Lab Soars 5.06% as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China

Stock Track
·
Dec 24, 2025

HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China

Stock News
·
Dec 24, 2025

HK Stock Connect Shareholding Changes as of December 24

Stock News
·
Dec 24, 2025

Zai Lab Wins NMPA Approval for COBENFY Schizophrenia Treatment in China

Reuters
·
Dec 23, 2025

Zai Lab Announces Approval of Cobenfy (Xanomeline and Trospium Chloride) in China, a First-in-Class Therapy for Schizophrenia

THOMSON REUTERS
·
Dec 23, 2025

Zai Lab Chief Legal Officer Frazor Titus Edmondson III Reports Disposal of Common Shares

Reuters
·
Dec 19, 2025

HKEX 52-Week Highs and Lows | Dec 16

Stock News
·
Dec 16, 2025

Hong Kong Stocks Hit 52-Week Highs and Lows | Dec 11

Stock News
·
Dec 11, 2025

BRIEF-Zai Lab Announces Dosing Of First Participant In Global Phase 1/1b Study Of ZL-1503, An IL-13/IL-31R Bispecific Antibody For Treatment Of Atopic Dermatitis

Reuters
·
Dec 08, 2025

Zai Lab Announces Dosing of First Participant in Global Phase 1/1B Study of Zl-1503, an Il-13/Il-31R Bispecific Antibody for the Treatment of Atopic Dermatitis

THOMSON REUTERS
·
Dec 08, 2025

Zai Lab Announces Updates to China’s National Reimbursement Drug List

THOMSON REUTERS
·
Dec 07, 2025

Zai Lab (09688) Announces Monthly Equity Changes for November 2025

Bulletin Express
·
Dec 04, 2025

HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%

Tiger Newspress
·
Dec 04, 2025

Zai Lab (09688) Grants Stock Options and Restricted Share Units

Stock News
·
Dec 03, 2025